Press Release Christine Mackenzie 9/17/26 Press Release Christine Mackenzie 9/17/26 Acelot Announces Initiation of Dosing in Phase Ia Clinical Trial of ACE-2223, a First-in-Class Oral Small Molecule Targeting Aggregated TDP-43 in Amyotrophic Lateral Sclerosis (ALS) Read More Press Release Christine Mackenzie 8/12/26 Press Release Christine Mackenzie 8/12/26 Acelot Announces Appointment of Mark Forman, M.D., Ph.D., as Chief Development Officer and Chief Medical Officer Read More
Press Release Christine Mackenzie 9/17/26 Press Release Christine Mackenzie 9/17/26 Acelot Announces Initiation of Dosing in Phase Ia Clinical Trial of ACE-2223, a First-in-Class Oral Small Molecule Targeting Aggregated TDP-43 in Amyotrophic Lateral Sclerosis (ALS) Read More
Press Release Christine Mackenzie 8/12/26 Press Release Christine Mackenzie 8/12/26 Acelot Announces Appointment of Mark Forman, M.D., Ph.D., as Chief Development Officer and Chief Medical Officer Read More
